← 返回 Avalaches

带状疱疹(herpes zoster)是由水痘带状疱疹病毒变种造成的再活化感染,会引发剧痛性皮疹,且可进展为带状疱疹后神经痛(PHN)等长期后遗症。文中指出「三分之一人生中可能罹患」;风险在50岁以上急遽上升,免疫力下降者亦高。疾病可在神经系统潜伏多年后被触发,诱因包括老化、免疫抑制与急性压力,并非单纯轻症。即使症状多在皮肤出现,也可能累及眼睛、脸部及罕见中枢神经,甚至导致脑炎;此外,感染后12个月内中风风险明显上升。

文章以73岁的 Ann Garner 为案例:她在面部感到刺痛与剧烈灼热后短时间内发展为红疹与水疱,疼痛持续且高强度,且一度需要镇静助眠。治疗建议包括在皮疹出现后72小时内使用 acyclovir,并搭配眼部药膏以减少眼部并发症;即使如此,她仍留下多年面部敏感与异常刺痛。她提到自己事前认为只是「轻微红疹」,这种认知偏差普遍存在。患者可因PHN陷入持续、无间歇的慢性痛苦,研究者也指出在五项涵盖2,519名患者的系统性回顾中,急性带状疱疹患者的身体健康量表平均低于常态15%,心理健康低13%,显示暂时性疾病也能造成显著且久长的生活品质下降。

文中还提到,临床上有患者甚至因持续痛苦而自杀,若伴认知受损或失智,影响更严重;罕见并发症如 pseudohernia 由神经损伤导致肌群控制丧失。预防上,英美皆建议在50岁以上或免疫功能受损成人接种带状疱疹疫苗,但实际接种率偏低:美国2022年仅约34%符合条件者接种至少一剂,英国2024年底至2025年1月为33%到45%,虽较高龄族群略佳。作者与专家都认为,公卫宣导不足导致民众仍把带状疱疹当作短期可忍受的病痛,忽略其可能变成终身神经痛的风险。

 

Shingles (herpes zoster) is a common reactivation of varicella zoster virus that causes a painful rash and can progress to post-herpetic neuralgia (PHN), a chronic pain state. One in three people may develop shingles, with risk rising sharply after age 50 or with weakened immunity. The virus may remain dormant for years in the nervous system and reactivate with aging, immunosuppression, or stress. Although often perceived as mild, it can affect the face and eyes and, in rare cases, the central nervous system. One study cited notes higher stroke risk in the 12 months after infection.

The article’s case of 73-year-old Ann Garner shows typical severity: she developed sudden tingling and severe burning pain, then rapid rash and blistering across her face and eyelid. She was advised to begin acyclovir within a 72-hour window, but still suffered prolonged pain. PHN persisted, leaving lingering hypersensitivity and tingling for at least a year. A 2022 systematic review of 2,519 patients reported quality-of-life scores 15% below physical-health norms and 13% below mental-health norms, showing a disease that is not usually fatal can still cause major long-term disability.

Vaccination remains the main prevention strategy, yet uptake is low. In the US, only about 34% of eligible adults had at least one dose in 2022; in the UK, coverage in late 2024 to early 2025 was 33–45%. UK policy focuses on routine vaccination at 65 or 70–79 years and on immunocompromised adults, while the US covers adults 50+ or 19+ if immune-compromised. The article emphasizes that people and governments underestimate the condition: many patients, including some in older age, endure relentless pain, rare complications such as pseudohernia, and, in extreme cases, severe outcomes including suicide from untreated suffering.
2026-04-20 (Monday) · 6d5705ec48bf024d1934f7aac31ac26e6c16ef4d